Capsida

AAV capsid engineering, targeted genetic medicines, in-house cGMP manufacturing

deliverydeliveringgene therapy

capsida.com·Newbury Park, California, United States·Founded 2019

01Overview 02People 03Projects 04Concepts 05Patents 06Public records 07Belief evolution

Plate C · C-HCCV

Summary · Eternal Search editorial

Capsida AAV capsid engineering, targeted genetic medicines, in-house cGMP manufacturing

Capsida is developing next-generation targeted genetic medicines for rare and more common neurological and ocular diseases. Its platform engineers AAV capsids intended to cross biological barriers and deliver gene therapies for CNS and eye indications. The company states that it integrates capsid engineering, preclinical work, and cGMP manufacturing capabilities in-house.

The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →

Plate C·01 · Scientific profile

All 16 dimensions
on the record.

Composite16

Chain scale100 pts

Dimensions16

Plate C·02 · Where it sits among peers

Score vs. proximity
to longevity goals.

Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.

Reading

Capsida — Translational · Bottom quartile. Derived deterministically from 8 extracted project(s). Most-advanced status: phase 1. Band: translational. Modifiers: +5 depth (2 programs at…

Source: Deterministic

At a glance

Webcapsida.com

HQNewbury Park, California, United States

Founded2019

Publications

7 on file

012026Identification of high-performing ocular AAV capsids through directed engineering across intravitreal and suprachoroidal delivery routes—→022025CAP-003: A Novel Investigational CNS-targeted Intravenous Gene Therapy for the Treatment of PD-GBA—→032023Intravenous functional gene transfer throughout the brain of non-human primates using AAV.Research square→042023Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain.Nature nanotechnology→052023Adeno-associated viral vectors for functional intravenous gene transfer throughout the non-human primate brain—→062022AAV capsid variants with brain-wide transgene expression and decreased liver targeting after intravenous delivery in mouse and marmoset—→072022Intravenous gene transfer throughout the brain of infant Old World primates using AAV—→

Loading

Loading section...

0-100 chain-logic scale · 15 dimensions · scored on public evidence

Capsida

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

Loading

All 16 dimensionson the record.

Score vs. proximityto longevity goals.

Publications

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.

All 16 dimensions
on the record.

Score vs. proximity
to longevity goals.